• PDF: Delivered by email usually within 24 to 48 UK business hours.

Botulinum Toxin

Botulinum Toxin

This report analyzes the worldwide markets for Botulinum Toxin in US$ Million by the following Product Segments: Cosmetic Applications, and Therapeutic Applications. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets.The report profiles 22 companies including many key and niche players such as Allergan, Inc., Ipsen Group, Lanzhou Institute of Biological Products, Metabiologics, Inc., Merz Pharmaceuticals GmbH, Mentor Corporation, Medy-Tox Incorporated, Medicis Pharmaceutical Corporation, Revance Therapeutics, Inc., and US WorldMeds. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

  • I.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
  • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study
  • Cosmetic Applications
  • Therapeutic Applications
  • II. EXECUTIVE SUMMARY
  • 1.INDUSTRY OVERVIEW
    • A Prelude
    • Current and Future Scenario
    • By Geographic Region
    • Botulinum Toxin: ""The Science, The Hopes & the Risks""
    • Developed Regions Continue to Hold Sway Over Global Botulinum Toxin Market
    • Developing Markets Not Far Behind, But Not Yet There...
    • Pharma Companies Keenly Eye Lucrative BT Market
  • 2.TRENDS & ISSUES
    • Acceptance for Cosmetic BTX Treatment Grows
    • Aging Population: A Weighty Demographic Driver
    • Unmet Medical Needs Encourage Off-Label Use: A Cause for Concern or Jubilation?
    • Urgent Need for Physician Education about Off Label Usage
    • High Voltage Ad Campaigns Boost Patient Awareness
    • Societal Pressure to Look Young, Drives up Demand for Facial Aesthetics
    • Financing of Non-Reimbursed Healthcare: The Need of the Hour
    • Combination Therapies: A Double Whammy Success
    • Short Lived Aesthetic Effects: A Strong Business Case for Revision Treatments
    • Consolidation Blows in the Aesthetic Healthcare Industry
    • Undesirable Side Effects: A Challenge to Reckon With
    • Immunogenicity Undermines Patient Compliance
    • Protein Free BTX Products - The Probable Answer for Immunogenicity
    • Antigenicity: One of the Most Problematic Issues in Drug Development
    • Stringent Regulations Delay Market Approval & Put Reimbursements in Limbo
    • Non-Injectable Alternatives to Turn On the Heat
    • Alternative Methods of Botulinum Application under Development - A Review
    • Fears of Terrorism & Biological Warfare Thwart International Trade
  • 3.PRODUCT/INDUSTRY DYNAMICS
    • Comparison of Botox®, Dysport® and Xeomin® by Indications and Year of Approval
    • Scarce Differentiation Between the Four Approved BTX Products
    • Comparison of Leading Neurotoxins - Botox, Dysport and Xeomin by Safety and Efficacy
    • Botox® - An Overview
    • Key Characteristics of Botox® and Botox® Cosmetic
    • Common Adverse Reactions with Botox
    • Approvals and Indications of Botox in Select Regions
    • Global Botox Sales Shoot Up, Competition Begins to Hurt Prospects
    • Migraine Indication to Bolster Allergan's Botox Sales
    • Allergan Commences Advertising for Botox in Migraine Settings in the US
    • Therapeutics to Offer Higher Prospects for Botox
    • Botox Therapeutic Approvals in the US by Indication
    • Dysport®
    • Key Characteristics of Dysport®
    • Ipsen Counts on New Indications for Future Growth of Dysport
    • Dysport Therapeutic Development Pipeline by Region
    • Dysport Cosmetic Development Pipeline by Region
    • Next Generation Dysport - A Breakthrough in BTX Market on the Cards
    • Xeomin®
    • Key Characteristics of Xeomin®
    • Xeomin Development Pipeline: Approved and Investigational Indications as of 2011
    • Global Expansion Helps Merz Gain in the BTX Market
    • Myobloc®/NeuroBloc®
    • Key Characteristics of Myobloc®
    • Myobloc - Still Long Way to Go...
    • Meditoxin®
    • Meditoxin® Expanding Its Wings across the Globe
    • PurTox®
    • Key Characteristics of PurTox®
    • PurTox Beckons Success in Clinical Trial Stage, Launch Still Years Away
    • RT001
    • Revance's RT001 -Potential Revolution in BTX Market under Development
    • How Does RT001 Work?
    • RT001 - A Potential Convenient Treatment Option for Hyperhydrosis Patients
  • 4.COMPETITION
    • Allergan Wields the Scepter
    • Allergan's Botox Faces the Heat of Competition
    • Market Share Statistics
    • Global
    • Table 1: Leading Products in the Global Botulinum Toxin Market (2011E): Percentage Breakdown of Revenue for Botox, Dysport, Xeomin and Others (includes corresponding Graph/Chart)
    • Table 2: World Market for Therapeutic Neurotoxins (2011E): Percentage Breakdown of Revenues by Brand -Botox, Dysport, Xeomin and Others (includes corresponding Graph/Chart)
    • Table 3: World Market for Cosmetic Neurotoxins (2011E): Percentage Breakdown of Revenues by Brand - Botox, Dysport, Xeomin and Others (includes corresponding Graph/Chart)
  • 5.PRODUCT OVERVIEW
    • Botulinum Toxin: A Poison That Cures
    • Structure & Mechanism of Action
    • Disadvantages
    • Classification of Botulinum Toxin
    • Botulinum Toxin Type A
    • Historical Timeline of Botulinum Toxin: 1885-2002
    • Botulinum Toxin Type B
    • Applications of Botulinum Toxin
    • Cosmetic Applications
    • Glabellar Lines
    • Facial Wrinkles
    • Key Cosmetic Indications for Botulinum Toxin
    • Therapeutic Applications
    • Movement Disorders/Pain
    • Cervical Dystonia
    • Hemifacial Spasm
    • Blepharospasm
    • Strabismus
    • Chronic Pain
    • Botox in Migraine Treatment
    • Hyperhidrosis
    • Bladder Dysfunctions
    • Spasticity
    • Other Applications
    • Side Effects
    • An Overview of Side Effects of BTX Treatment
    • Table 4: Side-Effects of BOTOX Treatment for Urinary Incontinence Associateh Neuromuscular Disorders: Percentage Breakdown of Major Conditions Reported Within 12 weeks of Injections during Phase III Clinical Trials (includes corresponding Graph/Chart)
    • Table 5: Side-Effects of BOTOX Treatment for Urinary Incontinence Associated with Neuromuscular Disorders: Percentage Breakdown of Major Conditions Reported Within 44 weeks of Injections during Phase III Clinical Trials (includes corresponding Graph/Chart)
  • 6.PRODUCT INTRODUCTIONS/APPROVALS
    • Botox Receives Health Canada Approval for Treating Neurogenic Bladder Condition
    • Allergan Obtains FDA Approval for New In -Vitro Cell-Based Assay for BOTOX
    • Merz Aesthetics Obtains FDA Approval for XEOMIN® for Treating Glabellar Lines
    • IMB Recommends Botox for Urinary Incontinence Management in Neurognenic OAB in EU
    • FDA Approves Botox for Treating Urinary Incontinence in Neurogenic OAB Patients
    • Allergan Receives Health Canada Approval for Botox for Treating Chronic Migraine
    • BOTOX® Receives Approval for Treating Chronic Headaches
    • Eisai's NerBloc Intramuscular Injection Approved for Sale in Japan.
    • SMC Approves the Use of Botox® for the Treatment of Focal Spasticity
    • FDA Grants Approval for Botox for Treating Migraine
    • MHRA Grants Approval for Botox for Treating Chronic Migraine
    • Allergan Receives FDA Approval for Botox for Treating Upper Limb Spasticity
    • Russian Authorities Approve Xeomin for Cosmetic Applications
    • Merz Launches Xeomin in the US
    • Ipsen Launches Dysport in US
    • Ipsen and Medicis Receives FDA Approval for Dysport™
    • Xeomin Receives Approval From European Health Authorities
    • Ranbaxy and MedyTox Collaborates to Launch Neuronox
    • GlaxoSmithKline Receives Approval for Botox Vista
    • Galderma and Ipsen Obtain Marketing Authorization for Azzalure
    • Azzalure® Gains Approval from 15 European Countries
    • Inclusion of New Side Effect in Botox and Botox Cosmetic Labels
    • Azzalure® Gains Approval for Aesthetic Application in the UK
    • Allergan and Clinique Launch New Skin Care Products
    • FDA Accepts Ipsen's Filing for Reloxin
    • GlaxoSmithKline Gains Approval for BOTOX® in Japan
    • Mentor Completes Phase IIIb Trial for Its Botulinum Toxin Type A Product
    • Allergan Commences Botox Study for Urological Cases in India
    • FDA Accepts BLA Filing for Dysport® in Cervical Dystonia Cases
    • Allergan Successfully Completes Analysis of Two Phase III Trials for BOTOX®
    • Allergan to Launch New Products in India
  • 7.RECENT INDUSTRY ACTIVITY
    • Amgen Inc Acquires Brazilian Company Bergamo
    • Ipsen and Syntaxin Forge Agreement to Formulate Novel Botulinum Toxin Product
    • Xoma Bags Federal Contract to Develop Broad-Spectrum Antitoxins
    • US WorldMeds Takes Over Solstice Neurosciences
    • Merz Pharma Acquires BioForm Medical
    • Johnson & Johnson Acquires Mentor Corporation
    • Merz Pharmaceuticals and Biolab Set Up Joint Venture
    • Ranbaxy Signs an in-Licensing Agreement with Medy-Tox
    • Ranbaxy Signs Marketing Agreement with MedyTox
    • Revance and Medicis Sign Licensing Agreement
    • GlaxoSmithKline and Wakamoto Pharmaceutical Collaborate to Market Botox
    • BioForm Medical Acquires Advanced Cosmetic Intervention
    • Galderma to Acquire CollaGenex
    • Allergan and Clinique Form Strategic Collaboration
    • Allergan to Set Up a New Subsidiary in India
    • Allergan Join Hands with India-Based Kaya
    • Q-Med and Medy-Tox Cancel the Collaboration Agreement
    • Galderma to Increase Awareness in Brazil
    • Galderma Receives License to Market Dysport
  • 8.FOCUS ON SELECT GLOBAL PLAYERS
    • Allergan, Inc. (US)
    • Ipsen Group (France)
    • Lanzhou Institute of Biological Products (China)
    • Metabiologics, Inc. (US)
    • Merz Pharma GmbH & Co. KGaA (Germany)
    • Mentor Corporation (US)
    • Medy-Tox Incorporated (South Korea)
    • Medicis Pharmaceutical Corporation (US)
    • Revance Therapeutics, Inc. (US)
    • US WorldMeds (US)
  • 9.GLOBAL MARKET PERSPECTIVE
    • Table 6: World Recent Past, Current & Future Analysis for Botulinum Toxin by Geographic Region/Country - US, Europe and Rest of World Markets Independently Analyzed by Annual Sales in US$ Million for the Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 7: World Historic Review for Botulinum Toxin by Geographic Region/Country - US, Europe and Rest of World Markets Independently Analyzed by Annual Sales in US$ Million For the Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 8: World 15-Year Perspective for Botulinum Toxin by Geographic Region - Percentage Breakdown of Dollar Sales for US, Europe and Rest of World Markets for the Years 2004, 2011 & 2018 (includes corresponding Graph/Chart)
    • Table 9: World Recent Past, Current & Future Analysis for Botulinum Toxin in Cosmetic Applications by Geographic Region - US, Europe and Rest of World Markets Independently Analyzed by Annual Sales in US$ Million for the Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 10: World Historic Review for Botulinum Toxin in Cosmetic Applications by Geographic Region - US, Europe and Rest of World Markets Independently Analyzed by Annual Sales in US$ Million for the Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 11: World 15-Year Perspective for Botulinum Toxin in Cosmetic Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Europe and Rest of World Markets for the Years 2004, 2011 & 2018 (includes corresponding Graph/Chart)
    • Table 12: World Recent Past, Current & Future Analysis for Botulinum Toxin in Therapeutic Applications by Geographic Region - US, Europe and Rest of World Markets Independently Analyzed by Annual Sales in US$ Million for the Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 13: World Historic Review for Botulinum Toxin in Therapeutic Applications by Geographic Region - US, Europe and Rest of World Markets Independently Analyzed by Annual Sales in US$ Million for the Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 14: World 15-Year Perspective for Botulinum Toxin in Therapeutic Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Europe and Rest of World Markets for the Years 2004, 2011 & 2018 (includes corresponding Graph/Chart)
    • III. MARKET
  • 1.THE UNITED STATES
    • A. Market Analysis
    • Current and Future Scenario
    • Cosmetic Procedures: An Overview
    • Major Market Trends
    • Botulinum Toxin to Drive Growth in the Facial Aesthetics Market
    • Competition Heats Up in the US BTX Market
    • Booming Non-Surgical Treatments
    • Aging Baby Boomers Drive Aesthetic Business
    • Expanding Physician Base Extends Impetus to Growth
    • Demand for Professional Help On the Rise
    • Direct-to-Consumer Advertising Drive Cosmetic Botulinum Toxin
    • Botulism Poisoning: A Major Concern
    • Botox Injection - Popular Non-Invasive Cosmetic Procedure
    • Recession Dents Cosmetic BTX Procedural Volume, Albeit Slightly
    • Table 15: US Cosmetic BTX Procedure Volume: 2007-2011 (includes corresponding Graph/Chart)
    • Botox Therapeutic to Drive Growth in Botox Franchise
    • Dysport Takes on Botox in the Therapeutic Space
    • Pricing and Promotions to Help Dysport Gain Market Share in Cosmetic Arena
    • Tremendous Prospects in Therapeutics Space for Dysport in the Long Run
    • Therapeutic BTX Market - New Entrants Slow in Gaining Market Share
    • Botox's Therapeutic Indications (Approved and Investigational) in the US by Year of Approval/Stage
    • Cosmetic BTX Market - Competition Threatens Botox Long-Term Dominance
    • Key BTX Products and Associated Fillers and Implants in the Cosmetic Botulinum Toxin Market
    • Market Opportunities for Botox in Migraine Beckons a Slow Star
    • Neurogenic OAB - A Relatively Smaller Market Opportunity
    • Idiopathic OAB Bodes Superior Prospects for Botox
    • Issues Persist in the Idiopathic OAB Space Dampening Prospects
    • Xeomin - Will the ""Pure"" Factor Finds Many Takers?
    • Xeomin Takes Big Leap in the US
    • Xeomin's Potential in the US Cosmetic Market
    • Merz Fortifies Position in the US Facial Injectables Market with BioForm Acquisition
    • PurTox Touted to Emerge as a Direct Competitor to Botox in the US
    • Competitive Landscape
    • Botox Leads the US Botulinum Toxin Market
    • Market Share Statistics
    • Table 16: US Market for Therapeutic Neurotoxins (2011E): Percentage Breakdown of Revenues by Brand - Botox, Myobloc, Dysport and Xeomin (includes corresponding Graph/Chart)
    • Table 17: US Market for Aesthetic Neurotoxins (2011E): Percentage Breakdown of Revenues by Brand - Botox and Dysport (includes corresponding Graph/Chart)
    • Product Approvals/Launches
    • Strategic Corporate Developments
    • Key Players
    • B. Market Analytics
    • Table 18: US Recent Past, Current & Future Analysis for Botulinum Toxin by Application - Cosmetic Applications and Therapeutic Applications Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 19: US Historic Review for Botulinum Toxin by Application - Cosmetic Applications and Therapeutic Applications Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 20: US 15-Year Perspective for Botulinum Toxin by Application - Percentage Breakdown of Dollar Sales for Cosmetic Applications and Therapeutic Applications Markets for the Years 2004, 2011 & 2018 (includes corresponding Graph/Chart)
  • 2.EUROPE
    • A. Market Analysis
    • Current and Future Scenario
    • European BTX Cosmetics Treatments Market - A Primer
    • Botox Approvals and Indications in Select European Countries
    • Botox to Support Radiation Treatments
    • Botox Loses Market to New Entrants in Europe
    • Galderma's Azzalure Makes Market Entry in Europe, Gains Share from Botox
    • Russia Mandates Registration of BTX Drugs
    • Market Share Statistics
    • Table 21: European Market for Therapeutic Neurotoxins (2011E): Percentage Breakdown of Revenues by Brand -Botox, Dysport, Xeomin, and Neurobloc (includes corresponding Graph/Chart)
    • Table 22: European Market for Cosmetic Neurotoxins (2011E): Percentage Breakdown of Revenues by Brand - Botox (Vistabel/Vistabex), Dysport and Xeomin (includes corresponding Graph/Chart)
    • Product Approvals and Launches
    • Strategic Corporate Development
    • Key Players
    • B. Market Analytics
    • Table 23: European Recent Past, Current & Future Analysis for Botulinum Toxin by Application - Cosmetic Applications and Therapeutic Applications Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 24: European Historic Review for Botulinum Toxin by Application -Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 25: European 15-Year Perspective for Botulinum Toxin by Application - Percentage Breakdown of Dollar Sales for Cosmetic Applications and Therapeutic Applications Markets for the Years 2004, 2011 & 2018 (includes corresponding Graph/Chart)
  • 3.REST OF WORLD
    • A. Market Analysis
    • Current and Future Scenario
    • A Peek into Select Markets
    • India - An Emerging Market for Botox
    • South Korean BTX Market - An Overview
    • Table 26: Botulinum Toxin Demand in South Korea: 2007- 2011E List of Botulinum Toxin Products Sold in South Korea by Year of Launch (includes corresponding Graph/Chart)
    • List of Botulinum Toxin Products Sold in South Korea by Year of Launch
    • Meditoxin Dominates Domestic BTX Market
    • Table 27: Korean Botulinum Toxin Market (2010): Percentage Breakdown of Sales by Leading Players -Medy-Tox, Allergan, Ipsen, and Lanzhou Institute (includes corresponding Graph/Chart)
    • Australia - A Well Supported Market
    • Botox Approvals and Indications in Select Asian Countries
    • Latin America- Cosmetic Surgery Market
    • Botox Approvals and Indications in Select Latin American Regions
    • Botox Approvals and Indications in Other Select Global Regions
    • Product Approvals and Launches
    • Strategic Corporate Developments
    • Key Players
    • B. Market Analytics
    • Table 28: Rest of World Recent Past, Current & Future Analysis for Botulinum Toxin by Application - Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 29: Rest of World Historic Review for Botulinum Toxin by Application - Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 30: Rest of World 15-Year Perspective for Botulinum Toxin by Application - Percentage Breakdown of Dollar Sales for Cosmetic Applications and Therapeutic Applications Markets for the Years 2004, 2011 & 2018 (includes corresponding Graph/Chart)
    • IV. COMPETITIVE LANDSCAPE
    • Total Companies Profiled: 22 (including Divisions/Subsidiaries - 26)
    • Region/CountryPlayers
    • The United States
    • Japan
    • Europe
    • France
    • Germany
    • The United Kingdom
    • Rest of Europe
    • Asia-Pacific (Excluding Japan)

Click here to view the full TOC

+44 20 8816 8548

Ask a question about Botulinum Toxin

Enter the characters you see in the picture below
Captcha